-1753359733653.webp&w=3840&q=75)
2025 NOSCM | HER2 Positive Breast Cancer: Individualizing Treatment to Biology and Response
0% Complete
Course Overview
Dr. Mark Pegram discussed the DESTINY-Breast09 trial, showing superior PFS with tucatinib plus pertuzumab.
Course Content
Credits
- AMA PRA Category 1 Credit™Non-CME
Course Details
- Duration
- 0.00 hour
- Released
- Jul 25, 2025
- Last Review
- Jul 25, 2025
- Expires
- Jul 25, 2026
Target Audience
Physicians
Nurses
Pharmacists
Physician Associates
Faculty & Disclosure
Faculty
Mark Pegram, MD
Accreditation
NA
